Progress in the development of an Advax-adjuvanted protein capsular matrix vaccine against typhoid fever
Microbes & Immunity · 2024
DOI: 10.36922/mi.4497 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbes & Immunity, 2024. Verfasst von Nikolai Petrovsky und 1 weiteren Autor:innen. Beteiligte Einrichtung: Vaxine Pty Ltd, 11-13 Walkley Avenue, Warradale, South Australia, Australia. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.
Abstract (Originalsprache)
Typhoid fever, caused by Salmonella Typhi, remains a significant global public health concern, with an estimated 11 – 20 million cases annually. Vaccines are critical to controlling typhoid fever. Widespread vaccination diminishes the emergence of antibiotic-resistant strains of S. Typhi. The economic benefits of vaccination are also substantial, as the costs of treating typhoid fever and its complications can be significant. Ty21a®, a killed whole-cell vaccine, and Vivotif®, a live-attenuated vaccine, have been available for decades but have relatively short durations of action and only provide partial protection. Vi polysaccharide-conjugate vaccines have improved the durability of protection, but there is still room for improvement. Typhax™, a novel alternative to traditional conjugate vaccines, utilizes Vi polysaccharide that is non-covalently entrapped in a poly-L-lysine and CRM197 protein matrix crosslinked by glutaraldehyde. When formulated with Advax-CpG™ adjuvant, Typhax demonstrated promising results in a range of animal models including mice, rabbits, and non-human primates in which it induces high and sustained serum anti-Vi immunoglobulin G and serum bactericidal activity, without any safety or reactogenicity issues. This novel vaccine approach offers the potential for a low-cost, more effective, and durable vaccine against typhoid fever, avoiding the need for frequent booster doses.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Vaxine Pty Ltd, 11-13 Walkley Avenue, Warradale, South Australia, Australia.
- Matrivax Research and Development Corporation, Boston, Massachusetts, United States of America.
Förderung
- NIAID NIH HHS
Zitieren
APA
Petrovsky, N., & Killeen, K. P. (2024). Progress in the development of an Advax-adjuvanted protein capsular matrix vaccine against typhoid fever. Microbes & Immunity. https://doi.org/10.36922/mi.4497
Vancouver
Petrovsky N, Killeen KP. Progress in the development of an Advax-adjuvanted protein capsular matrix vaccine against typhoid fever. Microbes & Immunity. 2024. doi:10.36922/mi.4497
BibTeX
@article{Petrovsky2024,
author = {Petrovsky, Nikolai and Killeen, Kevin P},
title = {Progress in the development of an Advax-adjuvanted protein capsular matrix vaccine against typhoid fever},
journal = {Microbes & Immunity},
year = {2024},
doi = {10.36922/mi.4497}
}
EUVIMED